May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Isolated Hyperglycemia Does Not Affect Intraocular Growth Factors In Humans
Author Affiliations & Notes
  • K. Höhne
    Clinical Nutrition, German Institute for Human Nutrition, Bergholz–Rehbruecke, Germany
    Dept. of Ophthalmology, Charité–Universitymedicine, Campus Benjamin Franklin, Berlin, Germany
  • H. Heimann
    Dept. of Ophthalmology, Charité–Universitymedicine, Campus Benjamin Franklin, Berlin, Germany
  • I. Göhring
    Clinical Nutrition, German Institute for Human Nutrition, Bergholz–Rehbruecke, Germany
  • M.H. Foerster
    Dept. of Ophthalmology, Charité–Universitymedicine, Campus Benjamin Franklin, Berlin, Germany
  • A.F. H. Pfeiffer
    Clinical Nutrition, German Institute for Human Nutrition, Bergholz–Rehbruecke, Germany
  • J. Spranger
    Clinical Nutrition, German Institute for Human Nutrition, Bergholz–Rehbruecke, Germany
  • Footnotes
    Commercial Relationships  K. Höhne, None; H. Heimann, None; I. Göhring, None; M.H. Foerster, None; A.F.H. Pfeiffer, None; J. Spranger, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4162. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Höhne, H. Heimann, I. Göhring, M.H. Foerster, A.F. H. Pfeiffer, J. Spranger; Isolated Hyperglycemia Does Not Affect Intraocular Growth Factors In Humans . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4162.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Intraocular concentration of Pigment epithelium–derived factor (PEDF) is decreased in proliferative diabetic retinopathy. However, regulation of PEDF in early stages of diabetes is unclear yet. We thus investigated vitreous levels of PEDF and VEGF in diabetes patients without diabetic retinopathy. Methods:We obtained 47 vitreous samples of 47 patients undergoing pars plana vitrectomy due to macular hole, epiretinal gliosis or rhegmatogenous retinal detachment. 40 nondiabetic control patients and 7 patients with type 2 diabetes but without signs of diabetic retinopathy were compared. A polyclonal PEDF–specific antibody was produced by immunisation of rabbits with recombinant PEDF expressed in HEK293 cells. Vitreous levels were determined by Western blot with this ab and additionally with a commercial monoclonal ab (Chemicon, Temecula). VEGF was measured by ELISA (R&D Systems, Minneapolis). Albumin levels were measured by standard techniques. Statistical analysis was performed by Mann–Whitney–U–test or Chi–Square test. All results are provided as mean ± SEM. Results:Diabetes patients had a higher mean fasting glucose and HbA1c as expected (7.5±1.9mmol/L, 7.6±0.9% vs. 5.5±0.7mmol/L (p<0.001), 5.9±0.6% (p<0.001), respectively). None of the diabetes patients had any sign of diabetic retinopathy. PEDF Western blot yielded one specific band at the predicted size of 49 kDa. This band disappeared after preincubation of the first antibody with recombinant PEDF (competition), thus showing specificity of the band. PEDF was found in comparable concentrations as in previous studies. However, there was no significant difference between both groups (3.73±0,22µg/mL in controls vs. 3.50±0.56µg/mL in the diabetic group; p=0.757). We also did not find different levels of VEGF in diabetes patients without diabetic retinopathy. VEGF was detectable in 13 [7.78 pg/mL(median)] controls and in one diabetic patient (5.7 pg/mL, p=0.349) Albumin concentration was 0.29 ± 0.06 mg/mL in controls and not statistically different from the diabetics with (0.24 ± 0.08, p=1.0) mg/mL. Conclusions:We conclude that intraocular concentrations of VEGF and PEDF are not changed in stages of hyperglycemia without existing diabetic retinopathy. Thus, growth factor changes are late in the pathogenesis of diabetic retinopathy and may require additional stimuli such as hypoxia or blood–retina barrier breakdown.

Keywords: diabetic retinopathy • vitreous • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×